This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo®: Treat the majority of patients with simple dosing and a flexible infusion time

Dose in adults and adolescents aged 12 to <18 years with a bodyweight of ≥ 33 kg and CrCL > 50 mL/min**¥1

No dosage adjustment is required for:

  • Elderly patients with CrCL > 50 ml/min
  • Adult patients according to body weight
  • Patients with hepatic impairment or mild renal impairment

Based on PK/PD analyses, the recommended dose regimen for treatment of cSSTI in adults due to confirmed or suspected S.aureus for which the Zinforo MIC is 2 or 4 mg/L is 600 mg every 8 hours using 2-hour infusions†1 

Zinforo can be used in patients with varying degrees of renal impairment1

Dosage in adults and adolescents aged from 12 to <18 years with bodyweight ≥ 33 kg and CrCL ≤ 50 mL/min**¥1

Zinforo PK/PD

Zinforo has relatively low protein binding (<20%), and using data comparing protein binding with rate of penetration to the site of infection, is predicted to have a rapid penetration rate5,6

At a dose of 600 mg every 12 hours and an MIC of 1 mg/L:​​​​​​​

  • 98.1% of patients would be expected to achieve a target free drug concentration above the MIC in plasma; for 600 mg every 8 hours, the proportion would be 100%6
  • 81.7% would be expected to achieve a target MIC in ELF6

Explore more

Zinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI¶1,5,7,8

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Learn more

** This is an optional area where footnotes can live.

*Applies only for standard dose regimens in adults and paediatrics, including patients with renal impairment. For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable. Prolonging the infusion duration may also help to manage infusion-related reactions (e.g. phlebitis)1
Infusion times of < 60 minutes and high-dose recommendations are based on PK/PD analyses only.1
Dose recommendations for the treatment of cSSTI caused by S.aureus for which the Zinforo MIC is ≤ 1 mg/L
** Calculated using the Cockcroft-Gault formula1
Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
​​​​​​​¥Calculated using the Schwartz formula for paediatric patients (in mL/min/1.73 m2). Dose is based on CrCL. CrCL should be closely monitored and the dose adjusted according to changing renal function.
§Ceftaroline is haemodialyzable; thus Zinforo hould be administered after haemodialysis on haemodialysis days.


Abbreviations
​​​​​​​
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CrCL, creatinine clearance; MIC, minimum inhibitory concentration.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

References
  1. ZINFORO. Summary of Product Characteristics
  2. Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–7
  3. Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9
  4. Mazuski JE, et al. Surg Infect 2017;18:1–76
  5. Drusano GL, et al. J Antimicrob Chemother 2011;66:iii61-7
  6. Riccobene TA, et al. Antimicrob Agents Chemother 2016;60:5849-57
  7. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18 
  8. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
PP-ZFO-GBR-0221. September 2021

Tolerability profile of Zinforo

Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials

View tolerability profile

** This is an optional area where footnotes can live.

Discover specific information on the use of Zinforo in neonates, infants and children here:

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No